Molecular Cancer Therapeutics

Top Research Topics at Molecular Cancer Therapeutics?

The objective of Molecular Cancer Therapeutics is to combine knowledge in the areas of Cancer research, Cancer, Pharmacology, Immunology and Cancer cell. Cell culture, Cell growth, Apoptosis, Kinase and In vivo are some topics wherein Cancer research research discussed in Molecular Cancer Therapeutics have an impact. The studies on Cell culture discussed can also contribute to research in the domains of Molecular biology and Cell.

The in-depth study on Cell growth also explores topics in the intersecting field of Cell cycle. Many of the studies tackled connect Apoptosis with a similar field of study like Cell biology. Research in Cancer discussed is concerned with the study of Internal medicine as a whole.

The studies in Internal medicine featured incorporate elements of Gastroenterology, Endocrinology and Oncology. It addresses concerns in Pharmacology which are intertwined with other disciplines, such as Protein kinase B, PI3K/AKT/mTOR pathway, Paclitaxel and Toxicity. The journal dives deep in exploring the relationship between the study of Immunology and Angiogenesis.

• Cancer research (52.41%)
• Cancer (34.10%)
• Pharmacology (20.83%)

What are the most cited papers published in the journal?

• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (1085 citations)
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (1062 citations)
• Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. (1012 citations)

Research areas of the most cited articles at Molecular Cancer Therapeutics:

The most cited publications primarily focus on research topics in Cancer research, Pharmacology, Molecular biology, Apoptosis and Cancer. The published articles hold forums on Cancer research that merge themes from other disciplines such as Endocrinology, Cell growth, Cancer cell, Immunology and Kinase. The study of Pharmacology in the journal papers encompasses disciplines such as In vivo, as well as fields such as In vitro, all of which overlap with one another.

What topics the last edition of the journal is best known for?

• Gene
• Cancer
• Internal medicine

The previous edition focused in particular on these issues:

Molecular Cancer Therapeutics tackles a plethora of topics, such as Cancer research, In vivo, Cancer, In vitro and Antibody. Cancer research research featured in it incorporates concerns from various other topics such as Cell culture, Cancer cell, Apoptosis, Immune system and Antigen. The works on Apoptosis deal in particular with Programmed cell death.

The subject of T cell, which is connected to the field of CD3, serves as the foundation of the Antigen research featured in Molecular Cancer Therapeutics. The research on In vivo featured in it combines topics in other fields like Cell, DNA damage, Antibody-drug conjugate, Cytotoxicity and Cytotoxic T cell. The Cancer research discussed is included in the broader subject of Internal medicine.

The most cited articles from the last journal are:

• HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. (13 citations)
• The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies (9 citations)
• Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Molecular Cancer Therapeutics (based on the number of publications) are:

• Razelle Kurzrock (81 papers) published 3 papers at the last edition, 1 more than at the previous edition,
• Daniel D. Von Hoff (57 papers) absent at the last edition,
• Yves Pommier (57 papers) published 2 papers at the last edition, 1 more than at the previous edition,
• Anthony W. Tolcher (55 papers) absent at the last edition,
• Paul Workman (45 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Molecular Cancer Therapeutics (based on the number of publications) are:

• University of Texas MD Anderson Cancer Center (596 papers) published 15 papers at the last edition, 6 more than at the previous edition,
• Harvard University (417 papers) published 14 papers at the last edition, 2 more than at the previous edition,
• National Institutes of Health (259 papers) published 8 papers at the last edition, 1 more than at the previous edition,
• Memorial Sloan Kettering Cancer Center (167 papers) published 8 papers at the last edition, 3 more than at the previous edition,
• AstraZeneca (149 papers) published 7 papers at the last edition, 3 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 5.81% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 27.75% were posted by at least one author from the top 10 institutions publishing in the journal. Another 13.22% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 17.18% of all publications and 41.85% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Options related to Molecular Cancer Therapeutics

In light of the deep dive into the world of Molecular Cancer Therapeutics, it's imperative to understand the multitude of career opportunities tied with this branch of science. Among the profusion of possibilities, a career in nursing specializing in oncology is one such prospect. Nurses with an expertise in oncology, specifically those involved in medical research, play a significant role in the planning and executing of therapeutic interventions for patients diagnosed with cancer.

For instance, besides providing direct patient care, oncology nurses often assist in the implementation of clinical trials, contribute to the development of oncology care protocols, and serve as patient navigators during the continuum of cancer care. They can also further specialize in fields such as radiation, surgery, pediatric, or geriatric oncology, depending upon their interests and career goals.

For those considering a career in this realm, understanding state-specific licensing requirements is critical. As an example, vermont nursing license requirements emphasizes the obligatory steps for procuring an authorization to practice nursing in Vermont, including fees, necessary certifications, and renewal processes. Additionally, they lean toward enhancing the understanding of policymakers, educators, and researchers about the nursing workforce in Vermont.

Ultimately, careers in Molecular Cancer Therapeutics, particularly in fields such as oncology nursing, offer a ways to cater towards the betterment of human health while also satisfying an intellectual curiosity for those fascinated by the complex mechanisms underlying cancer biology.